Aladar Szalay Sells 23,383 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 23,383 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $2.70, for a total value of $63,134.10. Following the completion of the sale, the insider now owns 716,438 shares of the company’s stock, valued at $1,934,382.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, September 11th, Aladar Szalay sold 31,376 shares of Genelux stock. The shares were sold at an average price of $2.62, for a total transaction of $82,205.12.
• On Tuesday, September 3rd, Aladar Szalay sold 42,818 shares of Genelux stock. The shares were sold at an average price of $2.09, for a total value of $89,489.62.
• On Thursday, August 29th, Aladar Szalay sold 107,045 shares of Genelux stock. The stock was sold at an average price of $1.98, for a total transaction of $211,949.10.
• On Tuesday, August 27th, Aladar Szalay sold 51,630 shares of Genelux stock. The stock was sold at an average price of $2.11, for a total transaction of $108,939.30.
• On Friday, August 23rd, Aladar Szalay sold 40,000 shares of Genelux stock. The stock was sold at an average price of $2.29, for a total value of $91,600.00.

Genelux Stock Performance

NASDAQ GNLX opened at $2.60 on Thursday. Genelux Co. has a fifty-two week low of $1.60 and a fifty-two week high of $30.44. The firm has a market capitalization of $89.32 million, a P/E ratio of -2.68 and a beta of -1.55. The stock has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $3.48.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts forecast that Genelux Co. will post -0.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GNLX. Roth Mkm initiated coverage on Genelux in a report on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price target for the company. Roth Capital raised shares of Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. Benchmark cut their target price on Genelux from $30.00 to $25.00 and set a “speculative buy” rating on the stock in a research report on Friday, May 31st. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $26.75.

Institutional Trading of Genelux

A number of hedge funds have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genelux in the 2nd quarter worth about $39,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Genelux in the second quarter valued at about $56,000. Miracle Mile Advisors LLC purchased a new stake in shares of Genelux during the second quarter worth about $58,000. New York State Common Retirement Fund raised its position in shares of Genelux by 17.6% during the 4th quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after purchasing an additional 966 shares during the last quarter. Finally, SageView Advisory Group LLC acquired a new position in shares of Genelux during the 1st quarter worth about $121,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.